Abstract
Background Multiple studies have reported the significance of the systemic immune-inflammation index (SII) in the prognosis of colorectal cancer (CRC), but no consensus has yet been reached. The purpose of this study was to systematically assess the prognostic value of SII in patients with CRC. Materials and Methods We performed a systematic literature search in PubMed, Embase, and the Cochrane Library for eligible studies. The correlation between pretreatment SII and overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) in CRC patients was evaluated by combining the hazard ratio (HR) and 95% confidence interval (CI). Results Twelve studies involving 3919 patients were included. Comprehensive analysis results showed that high SII indicated poor OS in CRC patients (HR = 1.777, 95% CI: 1.328-2.376). Compared with patients with low SII values, patients with high SII had lower PFS (HR = 1.658, 95% CI: 1.189-2.311). Subgroup analysis further verified the above results. Conclusions SII may be a noninvasive and powerful tool for predicting survival outcomes in CRC patients. However, more well-designed studies are needed to validate our findings.
Highlights
The latest epidemiological survey data shows that the incidence of colorectal cancer (CRC) ranks third and is the second leading cause of cancer-related deaths in the world [1]
The inclusion criteria were as follows: (1) articles exploring the relationship between systemic immune-inflammation index (SII) and the prognosis of CRC; (2) neutrophil, platelet, and lymphocyte counts measured before treatment, including surgery, neoadjuvant chemoradiotherapy, and chemoradiotherapy; (3) data including overall survival (OS), disease-free survival (DFS), or progression-free survival (PFS) and risk ratios (HRs), as well as the corresponding 95% confidence interval; (4) patient size greater than 50; (5) all patients included in the study being divided into two groups based on counting scores; and (6) all publications with full text written in English
Our results showed that high SII predicted poor OS for all subgroups
Summary
The latest epidemiological survey data shows that the incidence of colorectal cancer (CRC) ranks third and is the second leading cause of cancer-related deaths in the world [1]. Several studies have shown that the systemic immune-inflammation index (SII) is related to the prognosis of malignant tumors [4]. Several studies have shown that SII can be used as a valuable predictor of different treatment methods for CRC. Other studies have confirmed the prognostic value of SII to predict the efficacy of bevacizumab in mCRC [7, 9]. Multiple studies have reported the significance of the systemic immune-inflammation index (SII) in the prognosis of colorectal cancer (CRC), but no consensus has yet been reached. The purpose of this study was to systematically assess the prognostic value of SII in patients with CRC. Comprehensive analysis results showed that high SII indicated poor OS in CRC patients (HR = 1:777, 95% CI: 1.328-2.376). More well-designed studies are needed to validate our findings
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
